tirzepatide glp 1 and gip Explained: The Future of Weight Management Lose up to 20% of your body weight with this simple GLP-1/GIP dual agonist tirzepatide normalizes

Eli Lilly reported these results in mid-2025, and the retatrutide availability timeline now points toward potential FDA approval no earlier than 2027, as additional phase 3 trials continue

Berg, S., Stickle, H., Rose, S

Transform Your Body with Semaglutide GLP-1 Weight Loss Injections by Melanie Speed, APRN, NP-C, CANS in Las Vegas & Beverly Hills At The Beverly Hills MedSpa, Melanie Speed, APRN, NP-C, CANS , brings over 30 years of experience to Semaglutide GLP-1 weight loss injections

That said, our findings are consistent with the existing literature

Gibbons et al., studied the effect of oral semaglutide in 15 subjects with type 2 diabetes and reduction on appetite and craving, demonstrating not just the reduction in calorie intake, but also lowering the palatability and preference for sweet and high fat food (177)